Physician profile
Gregory Taylor
NPI 1871595843
$12,933.04
in general payments reported to CMS, 2019-2025
33 companies · $608 in 2025
The $608 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $97.67 · 2021: $353 · 2022: $3,907 · 2023: $4,288 · 2024: $3,043 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $6,493 · Food and Beverage: $1,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $6,492.72 |
| Food and Beverage | $1,445.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fuse Medical, INC. | $10,027.08 | 2022-2025 | Orbitum Staple System |
| Horizon Therapeutics Plc | $541.29 | 2019-2023 | Krystexxa |
| Bioventus LLC | $318.07 | 2025 | Exogen Ultrasound Bone Healing System |
| Smith+Nephew, INC. | $260.59 | 2019-2024 | Stravix, Grafix, Collagenase Santyl |
| Nevro Corp. | $256.16 | 2021-2023 | Senza |
| Treace Medical Concepts, INC. | $232.36 | 2022-2025 | |
| Melinta Therapeutics, LLC | $204.49 | 2019-2020 | |
| Forma Medical | $143.69 | 2025 | Optimalmtp |
| Amgen INC. | $123.65 | 2024 | Krystexxa |
| Medtronic, INC. | $117.34 | 2024 | Hawkone |
| Paragon 28, INC. | $103.75 | 2019 | |
| Paratek Pharmaceuticals, INC. | $71.84 | 2021-2022 | |
| Organogenesis INC. | $56.56 | 2022-2023 | Puraply |
| Merck Sharp & Dohme LLC | $56.27 | 2019 | |
| Trice Medical, INC. | $52.84 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sebela Pharmaceuticals INC. | $38.66 | 2019 | |
| Alfasigma USA, INC. | $32.02 | 2020-2021 | |
| Nabriva Therapeutics, Plc | $31.59 | 2021-2022 | |
| Misonix INC | $27.80 | 2019 | |
| Omeza LLC | $24.27 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $22.72 | 2024 | |
| Hikma Pharmaceuticals USA | $21.24 | 2019 | |
| Arthrosurface Incorporated | $19.80 | 2019 | |
| Triad Life Sciences INC. | $19.00 | 2022 | |
| Zyla Life Sciences, INC. | $18.34 | 2019 | |
| Ermi LLC | $17.78 | 2022 | |
| Wright Medical Technology, INC. | $17.72 | 2019 | |
| Axogen | $15.61 | 2019 | |
| Amniox Medical, INC. | $15.01 | 2019 | |
| Hydrofera LLC | $13.21 | 2023 | Hydrofera Blue |
| Reprise Biomedical, INC. | $12.28 | 2022 | |
| Integra Lifesciences Corporation | $10.83 | 2019 | |
| Alafair Biosciences, INC. | $9.18 | 2025 | Versawrap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.